Janssen Targets Combinations As Next Step For Newly Approved Darzalex
This article was originally published in Scrip
Executive Summary
Johnson and Johnson company, Janssen Research and Development, believes it can take its newly approved multiple myeloma therapy Darzalex (daratumumab) one step further by combining it with Revlimid (lenalidomide) and dexamethasone.
You may also be interested in...
CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma
Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.